rosiglitazone has been researched along with Heart Disease, Ischemic in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, ZF; He, WX; Huang, SQ; Huang, YJ; Jiang, LL; Li, B; Li, CJ; Li, SH; Song, XW; Su, T; Wu, H; Zhang, BL | 1 |
| Hoffstad, O; Margolis, DJ; Strom, BL | 1 |
| Cobitz, A; Heise, M; Koch, G; Louridas, B; McMorn, S; Semigran, M; Sowell, M; Zambanini, A | 1 |
| Furberg, CD; Singh, S | 1 |
| Sinclair, A; Viljoen, A | 1 |
| Bolger, AF; Eckel, RH; Giugliano, RP; Herrington, D; Kaul, S | 1 |
| Nissen, SE | 1 |
| Rosen, CJ | 2 |
| Gelperin, K; Graham, DJ | 1 |
| Bourg, CA; Phillips, BB | 1 |
| Pouwels, KB; van Grootheest, K | 1 |
| Chattipakorn, N; Chattipakorn, SC; Chinda, K; Palee, S; Weerateerangkul, P | 1 |
| Christopher, TA; Gao, E; Liu, HR; Lopez, BL; Ma, XL; Ohlstein, EH; Tao, L; Willette, RN; Yue, TL | 1 |
| Krall, RL | 1 |
| Schatz, DA; Shuster, JJ | 1 |
| Buckingham, RE; Clarke, K; Cole, MA; Desrois, M; Draper, NJ; Sidell, RJ | 1 |
2 review(s) available for rosiglitazone and Heart Disease, Ischemic
| Article | Year |
|---|---|
Safety and efficacy of rosiglitazone in the elderly diabetic patient.
Topics: Age Factors; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Ischemia; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.
Topics: Drug Labeling; Humans; Hypoglycemic Agents; Myocardial Ischemia; Risk; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2012 |
15 other study(ies) available for rosiglitazone and Heart Disease, Ischemic
| Article | Year |
|---|---|
Abnormal expression of PRKAG2-AS results in dysfunction of cardiomyocytes through regulating PRKAG2 transcription by interacting with PPARG.
Topics: AMP-Activated Protein Kinases; Apoptosis; DNA Methylation; Heart Failure; Humans; Hypoxia; In Situ Hybridization, Fluorescence; Myocardial Ischemia; Myocytes, Cardiac; PPAR gamma; RNA, Long Noncoding; Rosiglitazone | 2023 |
Association between serious ischemic cardiac outcomes and medications used to treat diabetes.
Topics: Adult; Aged; Biguanides; Cohort Studies; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Myocardial Ischemia; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2008 |
A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Ischemia; Odds Ratio; Randomized Controlled Trials as Topic; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors | 2008 |
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heart Failure; Humans; Myocardial Ischemia; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.
Topics: American Heart Association; Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Ischemia; Pioglitazone; Rosiglitazone; Societies, Medical; Thiazolidinediones; United States | 2010 |
The painful truth.
Topics: Access to Information; Cholesterol, LDL; Diabetes Mellitus; Drug Industry; Heart Failure; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Ischemia; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Revisiting the rosiglitazone story--lessons learned.
Topics: Advisory Committees; Diabetes Mellitus, Type 2; Drug Labeling; Government Regulation; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Ischemia; Odds Ratio; Pioglitazone; PPAR gamma; Product Recalls and Withdrawals; Research Design; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
FDA on rosiglitazone. More on advisory committee decision.
Topics: Humans; Hypoglycemic Agents; Myocardial Ischemia; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
The rosiglitazone decision process at FDA and EMA. What should we learn?
Topics: Contraindications; Diabetes Mellitus, Type 2; Drug Approval; Drug Synergism; Drug Therapy, Combination; Europe; European Union; Guidelines as Topic; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Meta-Analysis as Topic; Myocardial Ischemia; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration | 2012 |
Mechanisms responsible for beneficial and adverse effects of rosiglitazone in a rat model of acute cardiac ischaemia-reperfusion.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Caspase 3; Caspase 8; Heart; Male; Mitochondria, Heart; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocytes, Cardiac; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2013 |
Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion.
Topics: Animals; Apoptosis; Diet; Enzyme Induction; Hypercholesterolemia; In Situ Nick-End Labeling; Male; MAP Kinase Signaling System; Myocardial Ischemia; Myocardial Reperfusion Injury; Nitric Oxide; Rabbits; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2004 |
The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Topics: Advisory Committees; Diabetes Mellitus, Type 2; Drug Approval; Drug Evaluation; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Ischemia; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
Rosiglitazone and the FDA.
Topics: Advisory Committees; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Ischemia; Risk; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2007 |
The rosigliazone meta-analysis: lessons for the future.
Topics: Death; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Myocardial Ischemia; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2008 |
Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Heart; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Myocardial Ischemia; Myocardial Reperfusion; Obesity; Organ Size; Perfusion; Rats; Rats, Zucker; Reference Values; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2002 |